In May, AACR's journals editors highlighted studies on CD28’s impact on CAR T-cell activity, the relationship between neurons and...
In the CAR-PRISM clinical trial, the CAR T-cell therapy ciltacabtagene autoleucel showed promise for treating high-risk smoldering myeloma.
In April 2026, AACR's journals editors highlighted studies on cancer survivors taking GLP-1 agonists, an immunotherapy-boosting bacteria, and more.
In the first quarter of 2026, the FDA issued nine approvals in oncology, including treatments for blood cancers, pancreatic...
Learn about smoldering myeloma and the first treatment approved by the U.S. Food and Drug Administration to prevent its...
Cancer Today's winter 2025-2026 issue covers delaying stem cell transplants in multiple myeloma, new treatments for brain metastases, and...
In the last quarter of 2025, the FDA announced 20 approvals in oncology, including treatments for lung cancer, multiple...
The countdown to the new year is nearly upon us, but no need to count down to the last...
In October 2025, AACR's journals editors highlighted studies on the anticancer function of an Alzheimer’s-related protein, small-molecule-drug conjugates, and...
From July 1 to September 30, 2025, the FDA issued eight new oncology approvals, expanding treatment options for patients...